What changed
$TMO — HOLD 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $11.0B | EPS $5.44 vs $5.24 🟢 | Margin 21.8%
💡 Consensus expects steady mid-single-digit growth, consistent with recent quarters. Our variant view is that the PPI Business System and recent product launches could drive modest margin upside, but the market already prices this in; the Q1 beat was small and forward guidance remains key.
📉 Reward/risk: 1.33:1
🏢 Business Quality: 9/10 - Diversified life sciences and diagnostics giant with strong recurring revenue, wide moat, and consistent free cash flow generation.
📊 Valuation: fair — trailing P/E 26.6x (50th percentile of its own history), in line with peers (Danaher ~30x, Agilent ~25x); no significant discount to intrinsic...
🔮 Catalyst: Next quarterly earnings release (likely July 2026)
💰 Entry: $460, stop $430, target $500
📊 Our read: HOLD. Full analysis →
https://stockduty.xyz/s/TMO0620